While monogenic obesity treatments, such as injectable melanocortin-4 receptor (MC4R) agonists, have shown efficacy in addressing mutations like those in leptin receptors (LEPR), such interventions are less applicable to polygenic obesity, which involves numerous variants with small cumulative effects [23]. The gene discussed is LEPR; the disease is obesity due to melanocortin 4 receptor deficiency.